ALA-1300 has received a notice of allowance from The National Office of Intellectual Property of Vietnam (NOIP) after the examination. (Patent Application No. 1-2020-06145)
2022
ALA-1000 received notice of patent allowance from National Institute of Industrial Property Institute (INAPI), Chile on August 10, Application No. 624-2019
ALA-1000 received notice of patent allowance from European Patent Office (EPO) on May 12 , Application No. 17850245.6
ALA-1000 received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI on May 12, Application No. 000487-2019/DIN
ALA-1000 received notice of patent allowance from Intellectual Property Office of India on May 6, Application No. 201947006642
ALA-1000 received notice of patent allowance from Intellectual Property Office of Singapore (IPOS) on April 21, Application No. 11201901294Q
Alar announces Significant Progress on Developing long-acting Buprenorphine Injectable ALA-1000 on January 13
2021
ALA-1000 received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia on November 30, Application No. P00201902139
Alar announced results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients on November 9
ALA-1000 received notice of patent allowance from Intellectual Property Office of Vietnam on October 29, Application No. 1-2019-01258
Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder on October 28
ALA-1000 received notice of patent allowance from Taiwan Intellectual Property Office (TIPO) on September 3, Application No. 106131215
ALA-1000 received notice of patent allowance from South Africa-Companies and Intellectual Property Commission Department of Trade and Industry (CIPC) on August 25, Application No. 201900890
ALA-1000 received notice of patent allowance from Japan Patent Office (JPO) on August 3, Application No. 特願2019-535434
ALA-1000 received notice of patent allowance from Innovation, Science and Economic Development Canada (ISED) on May 10, Application No.3,033,046
ALA-1000 received notice of patent allowance from the IP New Zealand on April 30. Patent No. 750367
ALA-1000 received notice of allowance for patent registration from Korean Intellectual Property Office on April 16 (Application No. 10-2019-7009185)
ALA-1000 received Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) on April 12 (Application No. 2019102895)
2020
Listed on Taipei Exchange Market in Taiwan on September 23. Traded on October 5
ALA-1000 received notice of patent allowance from the IP Australia
ALA-3000 completed pre-IND Meeting with US FDA
ALA-1000 received notice of patent allowance from the Mexican Institute of Industrial Property (IMPI)
Approved to be a public offering company on June 3. Stock Code: 6785
ALA-1000 received notice of patent allowance from USPTO
ALA-1000 was approved by Ministry of Economic Affairs : A+ Industrial Innovation R&D Program (fast track)
2019
Approved by the Ministry of Economic Affairs as a Biotech Pharmaceutical company
ALA-1000 received US FDA IND approval
Approved to be located in Central Science Park
2017
ALA-1000 was approved by Ministry of Economic Affairs:A+ Industrial Innovation R&D Program-Industrial Technology Foresight Research Program